Printer Friendly

Articles from M2 Pharma (September 8, 2017)

1-31 out of 31 article(s)
Title Author Type Words
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis. Clinical report 159
American Brain Tumor Association elects Kelly Sitkin as chief advancement officer. 143
Amylyx to test lead therapeutic compound AMX0035 in partnership with Project ALS. 249
ASBM selects Madelaine Feldman as chairprson. 139
Bio-Techne Launches Zika Virus ELISA with Minimal Cross-reactivity with Dengue Virus. 333
Bioverativ signs research collaboration with Bicycle Therapeutics. 127
Bonesupport signs commercialisation agreement for its products in France with Novomedics. 214
Casamba to Integrate Kno2 Platform to Enhance Care Coordination Across Post-Acute, Ambulatory and Acute Settings. 341
Cellect discloses USD4.3m in gross proceeds in registered direct offering. 171
Dr Reddy's slapped with six major observations for Vishakapatnam plant. 175
Eli Lilly 'to continue with Cork expansion' despite worldwide job cuts. 226
Erytech Pharma reveals positive results from Phase 2b study. 193
Eton Pharmaceuticals elects Norbert Riedel to its board. 187
Galderma appoints Chris Chapman as VP & GM. 133
Galderma names new VPand General Manager of Prescription Business in US. 136
Global Health Solutions files US FDA 510(k) application for antimicrobial saturated petrolatum gauze, Hexagen Wound Dressing. 186
GSK exercises option on Adaptimmune's NY-ESO SPEAR T-cell therapy programme. 250
Institute of Pathology Heidelberg Joins Thermo Fisher Scientific Center of Excellence Programm. 365
Medifast's board approves USD0.32 per share dividend. 167
NCCN Doses First Patient in Collaborative Study of Bavituximab in Patients with Newly Diagnosed Glioblastomas. 401
Nektar Therapeutics Presents Study Data of NKTR-181 Investigational Opioid for Treatment of Chronic Pain at PAINWeek Conference. Conference news 321
New blood test developed by Roche and Foundation Medicine able to determine tumour mutational burden. 163
Novo Nordisk agrees to pay USD58.65m to settle Victoza charges. 146
Phreesia Achieves HITRUST CSF Certification for Enhanced Security and Compliance. 215
Prasco announces increase in ownership in Aprecia via stock purchase agreement. 193
Quest Diagnostics Now Utilises Nonfasting Cholesterol Testing with Improved Accuracy. 187
Recombinant DNA Technology Market to Reach USD 844.6bn by 2025, Grand View Research Forecasts. 514
Sanofi and Regeneron granted Breakthrough Therapy designation by FDA for cemiplimab. 243
Spinal Resources Inc passes US FDA's 510(k) clearence for iSwedge Pedicle Screw System for spinal rod surgeries. 246
Universal Health Realty authorises USD0.66 per share dividend. 114
Viking Therapeutics Study Data Support the Role of VK2809 in Improving Metabolic Control in Glycogen Storage Disease. 391

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters